Please login to the form below

Not currently logged in
Email:
Password:

Nabriva Therapeutics names Elyse Seltzer as CMO

She joins from GlaxoSmithKline

Clinical stage biopharma firm Nabriva Therapeutics has appointed Elyse Seltzer as chief medical officer.

The company is engaged on the research and development on novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

In her new role, Seltzer will supervise medical and regulatory aspects of clinical development and medical affairs, contributing to the company's clinical development strategy.

Commenting on her appointment, Seltzer said: “I am thrilled to join Nabriva. I am excited to have the opportunity to advance a novel class of antibacterials, particularly given the current and evolving challenges around resistance to currently available antibiotics. 

"I look forward to working with the highly experienced clinical team to fulfil this goal."

Seltzer joins Nabriva from GSK, where she was VP of global clinical sciences and operations. Prior to this, Seltzer was CMO at Tengion, a regenerative medicine company.

Dr Colin Broom, CEO of Nabriva, added: “We are very pleased to welcome Elyse to Nabriva. Her extensive experience in the anti-infective therapeutic area, and in leading international clinical development programs will enable us to efficiently advance our lead product, lefamulin, into late stage development for the treatment of CABP.”

Seltzer assumes the role from Dr William Prince, who will take up the position of senior VP of clinical science.

27th May 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics